Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high-inhibitor titres

Haemophilia

Volumn 12, Issue 1, 2006, Pages 100-102

  Tamura, Kazushi ^a   Kanazawa, T ^a   Suzuki, M ^a   Shioya, A ^a   Morikawa, A ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous infusion; Haemophilia; Immune tolerance; Inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BOLUS INJECTION; CASE REPORT; CHEMOPROPHYLAXIS; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; EMERGENCY SURGERY; EPIDURAL HEMATOMA; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LAMINECTOMY; MALE; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PRIORITY JOURNAL;

CHILD, PRESCHOOL; FACTOR VIII; HEMATOMA, EPIDURAL, SPINAL; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFUSIONS, INTRAVENOUS; MALE; TREATMENT OUTCOME;

EID: 33645980983     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01181.x     Document Type: Article

References (13)

1. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-24.
2. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Lindgren A, Wadenvik H, Tengborn L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia 2002; 8: 644-8.
4. Auerswald G, Prondzinski MVD, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
5. Brackmann HH, Gormsen J. Massive factor VIII infusion in haemophiliacs with factor VIII inhibitor, high responder. Lancet 1977 ; 2: 933.
6. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years' 'Bonn protocol'. Vox Sang 1996; 70 (Suppl. 1): 30-5.
7. Berntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70 (Suppl. 1): 36-41.
8. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 436-63.
9. Mariani G, Kroner B. Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success. Haematologia 2001; 86: 1186-93.
10. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
11. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in haemophilia A: A review. Semin Thromb Hemost 2003; 29: 69-75.
12. Kreuz W, Mentzer D, Auerswald G et al. Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1996; 2 (Suppl. 1): 19.
13. Tengborn L, Berntorp E. Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Haemophilia 1998; 4: 56-9.